Financial insights of BIO

MyFinsight

For the quarter ending 2025-09-30, BIO made $653,000K in revenue. -$341,900K in net income. Net profit margin of -52.36%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Net sales	653,000	651,600	585,400	649,729
Cost of goods sold	309,600	306,300	279,400	293,826
Gross profit	343,400	345,300	306,000	355,903
Selling, general and administrative expense	206,800	207,700	208,800	200,440
Research and development expense	71,300	60,500	73,500	90,997
Segment profit (loss)	65,300	77,100	23,700	64,466
Interest expense	12,300	12,600	12,000	12,174
Foreign exchange (gains) losses, net	2,900	-1,100	2,700	-1,641
Marketable securities, unrealized (gain) loss	-495,300	334,400	31,800	792,888
Other nonoperating income (expense)	8,300	16,200	37,200	18,081
Income (loss) from continuing operations before income taxes, noncontrolling interest	-431,100	414,000	83,400	861,620
(provision) benefit for income taxes	-89,200	96,200	19,400	208,448
Net income attributable to bio-rad	-341,900	317,800	64,000	653,172

Net income per share basic attributable to bio-rad	-12.7	11.67	2.29	23.37
Net income per share diluted attributable to bio-rad	-12.7	11.67	2.29	23.34
Weighted average common shares - basic	26,923,000	27,226,000	27,941,000	27,949,000
Weighted average common shares - diluted	26,923,000	27,228,000	27,955,000	27,985,000